Elli Papaemmanuil, PhD
@PapaemmanuilLab
Computational Oncology. Explores 🧬 tech, algorithms & data to improve diagnosis & treatment decisions in oncology. Opinions my own. Disclosures: http://bit.ly/3wpiP60
You can now access the IPSS-M through web, android and apple app store! Web: mds-foundation.org/mds-iwg-pm/ iOS: apps.apple.com/gb/app/ipss-m-… Android: play.google.com/store/apps/det…
On the eve of #ASCO25, it's #AcuteMyeloidLeukemia Thursday. Here are Top Posts of the Week! 🎉🎉🎉 1/ @PapaemmanuilLab on how patterns of co-mutations shape lineage composition + drive diverse cellular programs in AML: x.com/PapaemmanuilLa…
Phenotyping recurrent genomic architectures. Led by @MariaSirenko @soobeomlee & Z. Sun, our study @CellStemCell shows how patterns of co-mutations shape lineage composition + drive diverse cellular programs in AML. Awesome collaboration with @landau_lab @iannisaifantis1++🧵⬇️
Phenotyping recurrent genomic architectures. Led by @MariaSirenko @soobeomlee & Z. Sun, our study @CellStemCell shows how patterns of co-mutations shape lineage composition + drive diverse cellular programs in AML. Awesome collaboration with @landau_lab @iannisaifantis1++🧵⬇️
Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today @CellStemCell !! An amazing collaboration with @AkEisfeld & @PapaemmanuilLab & @landau_lab !!! Driven by the impressive @MariaSirenko…
#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/ea3211-study #BloodCancer #leukemia
Dr @sanamloghavi kicking off #2025PPLC on unifying disease classification in myeloid neoplasms + exemplifying the role of population based studies on criteria definition incl VAF, allelic state & patterns of co- mutations with data from our recent study brnw.ch/21wTSQI 🙌
Excited to share our latest study, led by @CLachowiez & @sanamloghavi on the relevance of data informed metrics in setting guidelines for disease classification in myeloid neoplasms.
Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with @sanamloghavi @PapaemmanuilLab @Elsa2Bernard and colleagues.
🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in @NatureGenet 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇
TP53 mutated AML…. surrounded by all of our failed therapies ….. #hemepath
Congratulations to @MSKCancerCenter MSK-IMPACT team and @OncoKB for receiving the #AACR25 TEAM Science Award! The impact of this team, assay & data to our understanding of cancer biology is unprecedented.
Excited to share our paper out today in @CellPressNews discovering RNA mis-splicing derived neoantigens & their cognate T cell receptors (TCRs) as well as characterization of endogenous neoantigen T cells in leukemia patients. authors.elsevier.com/sd/article/S00…
Tumor infiltrating clonal hematopoiesis associated with poor outcomes in solid tumors. Wonder if this is how IL1B inhibition seemed to improve survival from cancer in CANTOS… nejm.org/doi/full/10.10…
It has been unclear why cancer patients with CH have worse outcomes. Our work published @NEJM uncovers that Tumor infiltrating CH (TI-CH) has a direct role in immune remodelling of the TME with implications for tumor progression & treatment response. @MSKCancerCenter @TheCrick
New evidence today @NEJM that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…
Some trully trainee led science! @Elsa2Bernard @oriol_pich Maria Zagorulya - our work is done here! Read how CH can influence solid tumor progression & treatment response ⬇️ @NEJM with the one & only @CharlesSwanton @MSKCancerCenter @TheCrick
🚨Thrilled to share our latest work: “Tumor-Infiltrating Clonal Hematopoiesis” @NEJM - we investigated how age-related blood mutations impact cancer when they infiltrate tumors, with @Elsa2Bernard Maria Zagorulya, @PapaemmanuilLab @CharlesSwanton + more nejm.org/doi/full/10.10…
Coming back home, New York you are a city like no other 💛
As a co-founder of 23andMe, with all the recent news I felt it was time to express my views on the company, after witnessing the downfall of an idea and brand that could have become the world’s leading digital health platform. The idea for 23andMe came to me after years working…
👇me and @PapaemmanuilLab with front row seats at packed @ecuppen / @HartwigMedical-organized clinical cancer genome conference, rapt as @CharlesSwanton keynote unpacks ~5-10 years worth of unpublished data from his lab to basically solve never-smoker lung cancer 😮😲🙀🤯
BIG NEWS!
This is it people…. It’s really happening One unified #hemepath classification in the works…WHO 6th coming to you soon @SocforHemepath #USCAP2025
Hanging out with some of the very best @SocforHemepath #USCAP2025 Plus today I found out that dreams do come true... looking forward to a trully unifed classification for heme malignancies in the next WHO 📘 Let's get this done right this time!
Honorary guest alert at #USCAP25 Best hour of the day: listening to @PapaemmanuilLab describe the 10 yr journey of her lab dissecting the molecular mechanisms of myeloid neoplasia that have so significantly informed our field of #hemepath 👏🏼 @SocforHemepath